Meta-Analysis of Cohort Studies and Randomized Trials Progesterone and Breast Cancer
Evidence that Progesterone Protects Breast Tissue
Worldlink Medical Journal Club* Practitioners Discuss
the Impact of Progesterone on Breast Cancer Risk
Presented by Dr. Ashok Kadambi
(Click study image to download full text .pdf)
Meta analysis and systematic review published in Climacteric, January, 2018
Journal Club* panelist conclusions:
- estrogens increase breast tissue proliferation
- micronized progesterone reduces breast density
- synthetic progestogens do not reduce breast density
- micronized progesterone had a relative risk ratio for breast cancer of 0.67 to 0.9 when compared to synthetic progestogens
- relative risk of breast cancer is 1.4 to 1.98 with synthetic progestogens
- increased breast cancer risk persists after 5 years of treatment (RR=1.34) with synthetic progestogens
- Dr. Kadambi tells his patients "5 years have been shown to be absolutely safe . . . Why don't we do [progesterone+estradiol] for 5 years, then reassess every 5 years?"
Membership with Worldlink Medical offers exclusive access to tools that help you educate your patients more effectively.
Monthly Journal Clubs*, like the one this excerpt was taken from, give you in-depth insight into important studies about optimal hormones from experienced Worldlink practitioners.
Members dive deep into the evidence for optimizing bioidentical hormones in Journal Clubs and Webinars and get access to full text articles through EBSCO Research Library. Click the button to learn more.
In-depth analysis of the most important hormone studies (3 per month) by respected members of the Worldlink community
Dr. Neal Rouzier and other guest speakers present evidence-based pearls to treat your patients with proven protocols